Streetbeat News

Equity Actions

RNAZ

TransCode Therapeutics has announced a $3 million public offering of 10 million common shares at $0.30 per share. The proceeds will be used for product development, including clinical trials for its lead therapeutic candidate TTX-MC138, and for general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 6:21 am

FBP

First BanCorp has announced a new repurchase program of up to $250 million, which could include repurchases of common stock or junior subordinated debentures. Additionally, the company declared a quarterly cash dividend of $0.16 per share, payable on September 13, 2024. The repurchase program is expected to be executed through the end of Q4 2025.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 9:19 pm

CBFV

CB Financial Services announced a share repurchase program to buy back up to 5% of its outstanding common stock, totaling approximately $6.0 million. The program will end on July 25, 2025.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:58 pm

AROC

Archrock has commenced a public offering of 11 million shares of its common stock, with an option for underwriters to purchase an additional 1.65 million shares. The proceeds will be used to fund the acquisition of Total Operations and Production Services, LLC.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:54 pm

NTB

NTB Butterfield has approved a new share repurchase authorization for up to 2.1 million common shares.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:46 pm

CBFV

CB Financial Services has authorized a new stock repurchase program for up to 5% of its outstanding common stock. The program will terminate on July 25, 2025, regardless of whether the purchase is completed.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:45 pm

RNAZ

TransCode Therapeutics shares are trading lower following the announcement of a proposed public offering.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:44 pm

CLF

Cleveland-Cliffs Inc (NYSE:CLF) reported mixed Q2 earnings with revenue of $5.1 billion, missing estimates, but breakeven adjusted earnings beating expectations. The company generated strong free cash flow and continued cost-cutting initiatives. CLF repurchased 7.5 million shares and reduced debt by over $200 million. The company lowered its full-year 2024 capital expenditures forecast and expects further cost reductions in Q3.

Portfolio Pulse from Adam Eckert

July 22, 2024 | 8:29 pm

RNAZ

TransCode Therapeutics plans to offer shares of its common stock and/or pre-funded warrants in a best efforts public offering.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:11 pm

BWAY

Brainsway has filed for a mixed shelf offering of up to $100 million, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 8:05 pm